IBS Logo Primary.jpg
Intelligent Bio Solutions Expands Presence in the UK Retail Sector with Major Account Acquisitions
27 juin 2024 08h30 HE | Intelligent Bio Solutions, Inc.
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
IBS Logo Primary.jpg
Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and Logistics Sector
20 juin 2024 08h30 HE | Intelligent Bio Solutions, Inc.
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
IBS Logo Primary.jpg
Intelligent Bio Solutions Begins Subject Dosing and Sampling for FDA 510(k) Pharmacokinetic (PK) Study for its Intelligent Fingerprinting Drug Screening Technology
18 juin 2024 08h30 HE | Intelligent Bio Solutions, Inc.
NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
IBS Logo Primary.jpg
Intelligent Bio Solutions Implements Strategic Reorganization Plan to Support Global Growth Initiatives
13 juin 2024 08h30 HE | Intelligent Bio Solutions, Inc.
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
IBS Logo Primary.jpg
Intelligent Bio Solutions Adds Major European Transport and Infrastructure Solutions Provider to Growing Number of Accounts Adopting Fingerprint Drug Screening Technology
12 juin 2024 08h30 HE | Intelligent Bio Solutions, Inc.
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
IBS Logo Primary.jpg
Intelligent Bio Solutions to Participate in the Sidoti Small-Cap Conference on June 12-13, 2024
06 juin 2024 08h30 HE | Intelligent Bio Solutions, Inc.
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
IBS Logo Primary.jpg
Intelligent Bio Solutions Successfully Completes Recruitment and Begins Subject Screening for FDA 510(k) Pharmacokinetic (PK) Study
29 mai 2024 08h30 HE | Intelligent Bio Solutions, Inc.
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
IBS Logo Primary.jpg
Intelligent Bio Solutions Unveils Key Performance Indicator Growth in the United Kingdom as Drug Screening Industry Combats Drug Test Cheating and Searches for Simpler, Faster, Non-Invasive and More Cost-Effective Solutions
23 mai 2024 08h30 HE | Intelligent Bio Solutions, Inc.
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...
IBS Logo Primary.jpg
Innovative Fingerprint Drug Screening Solution Showcased at the UK's Premier Health and Safety Event
17 mai 2024 08h30 HE | Intelligent Bio Solutions, Inc.
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
IBS Logo Primary.jpg
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights
08 mai 2024 08h30 HE | Intelligent Bio Solutions, Inc.
Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024 Cash and cash equivalents as of March 31, 2024, was $9.40 million Commenced...